Cargando…
Optimizing the use of biological therapy in patients with inflammatory bowel disease
Biological therapy revolutionized the treatment of inflammatory bowel disease (IBD) during the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF), integrins or IL12/23, have been approved—or are in development for—both Crohn’s disease (CD) and ulcerative colitis (UC)....
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324872/ https://www.ncbi.nlm.nih.gov/pubmed/25567472 http://dx.doi.org/10.1093/gastro/gou087 |